aTYR PHARMA ATYR
NASDAQ ATYR
$0.17 +0.00 (+0.00%)
At close: Oct 23, 2026 · 4:00 PM EDT

aTYR PHARMA (ATYR) Gains from Sales and Divestitures (2019 - 2024)

Updated

aTYR PHARMA's Gains from Sales and Divestitures was $12,000 in FY2025, up 300.0% from $3,000 in FY2024.

Analysis

aTYR PHARMA (ATYR) Gains from Sales and Divestitures (2019 - 2024) Analysis & Trends

From FY2018 onward, aTYR PHARMA has reported Gains from Sales and Divestitures for 8 years.

  • The FY2025 figure marks the highest annual Gains from Sales and Divestitures since FY2022.
  • Per Business Quant data, Gains from Sales and Divestitures in earlier years was $3,000 in FY2024 (-50.0%), $6,000 in FY2023 (-93.5%), $92,000 in FY2022 and -$6,000 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn
10 aTYR PHARMA 16.67 Mn -276.34 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 3,000.00
Dec 31, 2023 -7,000.00
Jun 30, 2023 13,000.00
Dec 31, 2022 -3,000.00
Sep 30, 2022 6,000.00
Mar 31, 2022 89,000.00
Dec 31, 2020 7,000.00
Sep 30, 2020 -4,000.00
Mar 31, 2020 -6,000.00
Sep 30, 2019 25,000.00
API Access

aTYR PHARMA Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ATYR&period=max&api_key=YOUR_API_KEY